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Background: The burden of pregnancy complications associated with well defined, already established systemic
rheumatic diseases preexisting pregnancy such as rheumatoid arthritis, systemic lupus erythematosus or
scleroderma is well known. Systemic rheumatic diseases are characterized by a long natural history with few
symptoms, an undifferentiated picture or a remitting course making difficult a timely diagnosis. It has been
suggested that screening measures for these diseases could be useful but the impact of unrecognized systemic
rheumatic disorders on pregnancy outcome is unknown. The objective of the study was to evaluate the impact
of previously unrecognized systemic autoimmune rheumatic on the incidence of preeclampsia and fetal growth
restriction (FGR).
Methods: A longitudinal cohort-study with enrolment during the first trimester of pregnancy of women attending
routine antenatal care using a two-step approach with a self-reported questionnaire, autoantibody detection and
clinical evaluation of antibody-positive subjects. The incidence of FGR and preeclampsia in subjects with newly
diagnosed rheumatic diseases was compared to that of selected negative controls adjusting for potential
confounders by logistic regression analysis.
Results: The prevalence of previously unrecognized systemic rheumatic diseases was 0.4 % for rheumatoid arthritis
(19/5232), 0.25 % (13/5232) for systemic lupus erythematosus, 0.31 % (16/5232) for Sjögren’s syndrome, 0.3 % for
primary antiphospholipid syndrome (14/5232) and 0.11 % (6/5232) for other miscellaneous diseases.
Undifferentiated connective tissue disease was diagnosed in an additional 131 subjects (2.5 %). The incidence of
either FGR or preeclampsia was 6.1 % (36/594) among controls and 25.3 % (50/198) in subjects with unrecognized
rheumatic diseases (excess incidence = 3.9 % (95 % CI = 2.6–9.6) or 34 % (95 % CI = 22–44) of all cases of
FGR/preeclampsia). The incidence of small for gestational age infant (SGA) was higher among subjects with
unrecognized rheumatic diseases (41/198 as compared to 46/594; adjOdds Ratio = 3.1, 95 % CI =1.96–4.95) than
in controls. The excess incidence associated with unrecognized rheumatic diseases was 2.7 % (95 % CI = 1.5–4)
or 25 % (95 % CI = 12.8–34.8) of all SGA cases.
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Conclusions: Unrecognized autoimmune systemic rheumatic disorders are associated with a significant proportion
of preeclampsia and fetal growth failure, suggesting that their role in the etiology of adverse pregnancy outcome is
probably undervalued.
Keywords: Autoimmune rheumatic diseases, Preeclampsia: Fetal growth restriction, Pregnancy, Connective tissue
diseasesTable 1 Ten-item questionnaire administered
1. Have you ever had generalised or localized reddening of your skinBackground
The major systemic autoimmune rheumatic diseases,
including rheumatoid arthritis (RA), systemic lupus
erythematous (SLE), Sjögren’s syndrome, and other con-
nective tissue diseases are relatively common in the general
population, with a lifetime risk of 8.4 % among women [1].
It has been estimated that approximately one in 12 women
will develop a definite inflammatory rheumatic disease
during her lifetime [1]. In addition, establishing and
emerging data suggest that the natural history of RA, SLE
and other autoimmune rheumatic disease encompasses a
so-called preclinical disease phase lasting from months to
several years and characterized by little or no clinical find-
ings and by the presence of detectable autoimmune anti-
bodies [2, 3]. These data suggest that autoantibodies and
autoimmune rheumatic diseases at various stages of deve-
lopment, often unrecognized or undiagnosed, are much
more common in the general population than previously
recognized [3, 4]. Systemic rheumatic disorders or the
preclinical stages of these diseases are not entirely benign
and have been associated with increased risks of subcli-
nical atherosclerosis, ischemic heart disease and lung
diseases [2, 5]. In addition, several studies have shown that
higher than expected rates of reproductive failures, fetal
growth restriction and preeclampsia occur before the
clinical occurrence or the diagnosis of rheumatic diseases
[6, 7], suggesting a potential causal role of unrecognized
or undiagnosed autoimmune disorders in the occurrence
of pregnancy complications. The purpose of this study
was to evaluate the prevalence of previously unrecognized
autoimmune rheumatic disorders during pregnancy and
to measure their impact on the incidence of fetal growth
failure and preeclampsia.after exposure to sunlight?
2. Have you ever had an obvious or prominent rash on your cheeks or nose?
3. Do your hands or your feet white in the cold and then blue or pink?
4. a. Have you ever had painful and swollen joints? b. Do you suffer
from stiffness lasting one hour or more in the morning?
5. Have you ever had pericarditis or pleuritis?
6. Do you have a dry mouth?
7. Do you feel like you have sand in your eyes?
8. Have you ever had painful white mouth ulcers?
9. Have you ever had thrombophlebitis?
10. Have you had two or more miscarriages or stillbirths?Methods
Subjects for the study were recruited among unselected
pregnant women who obtained antenatal care at our
Department during the first trimester of pregnancy. As
this was a cohort pilot study involving only a few mem-
bers of staff, we restricted the enrolment to all women
attending the clinic for antenatal care each Monday
during a 6-year period (May 2009 to June 2014). The
study was approved by the local ethics committee of our
Department (Procedure n.20110034530). Enrolment criteria
included: a) singleton pregnancy; b) antenatal care anddelivery at our Department; c) fluency in the Italian language;
d) no previous diagnosis or treatment of connective tissue
diseases; e) absence of fetal malformations or chromosomal
anomalies. The characteristics of the study and the validation
of the methods used have been already reported elsewhere
[8]. Briefly, after informed consent and before the medical
evaluation, each woman was asked to complete a screening
questionnaire including any connective tissue disorder
symptoms (Table 1). Women who answered positively to
one ormore of the questions were tested for the presence
of circulating autoantibodies, including antinuclear anti-
body (ANA), anti-double-stranded DNA, anti-extractable
nuclear antigen (ENA), anticardiolipin antibody, anti-
β2-glycoprotein I antibodies (aβ2GPI) and lupus anticoa-
gulant, according to standardized methods, as previously
described [9]. The ANA test was considered positive at a
titer ≥1:80. To ensure random sampling, the first three
subjects with negative responses to all the items in the
questionnaire after each index case diagnosed with a
rheumatic disease (major or undifferentiated connective
tissue diseases) and willing to participate in the study were
tested for autoantibodies and served as the control. Cases
and controls were referred to the rheumatology unit of
our hospital for further clinical assessment including a
careful history and a physical examination. Rheumato-
logists were unaware of the results of the questionnaires.
Rheumatoid factor and anti-citrullinated peptide anti-
bodies were not included in the screening autoantibody
profile, but were tested only in patients with arthritis after
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classified according to widely used criteria for undifferen-
tiated connective tissue disease (UCTD) [10], RA [11],
SLE [12], anti-phospholipid syndrome (APS) [13],
Sjögren’s syndrome [14], systemic sclerosis [15], polymyo-
sitis/dermatomyositis [16] and mixed connective tissue
disease [17]. Patients with suspected rheumatic disease
(symptoms plus autoantibodies) but not fulfilling the
abovementioned criteria were classified as the no criteria
for diagnosis group. Monthly rheumatological clinical
assessment during pregnancy was carried out in subjects
with major or undifferentiated connective tissue diseases
and in those without criteria for a definite diagnosis.
After Ist trimester enrolment, gestational age was
confirmed by ultrasound, and cases and controls were
followed-up with monthly obstetric clinical and ultrasono-
graphic evaluations. The mean uterine artery pulsatility
index (PI) in the first and second trimester was evaluated
according to standard methods [18]. Pulsatility indices of
uterine or umbilical arteries were considered abnormal
when the values were higher than the 95th percentile of
reference curves [18]. FGR was diagnosed when the
abdominal fetal circumference at ultrasonographic exam-
ination fell below the 10th percentile of our local reference
curves, confirmed on at least two consecutive measure-
ments taken 2 weeks apart after the standard US obtained
at 18–22 weeks of pregnancy, and PI of umbilical artery
was higher than the 95th percentile of reference curves sig-
naling a reduced perfusion of fetal placental unit. Pre-
eclampsia was diagnosed according to standard criteria
[19]. Small for gestational age infants were diagnosed
when birth weight was below the 10th percentile of the
Italian population [20].
Statistical analyses were carried out with one-way
analysis of variance and the Bonferroni post-hoc test to
compare continuous variables between the groups stud-
ied. Categorical variables were compared by Pearson’s χ2.
Partitioning of χ2 statistics with the Bonferroni correc-
tion for multiple comparisons was used to evaluate the
statistical significance of pairwise comparisons in two ×
K tables. Associations between the diagnostic category
of the rheumatic disorder and pregnancy outcomes were
evaluated using logistic regression analysis by computing
odds ratios and 95 % confidence intervals, adjusting
for potential confounders (Stata 12.0 for Windows.
(StataCorp LP, College Station, TX, USA).
Logistic models included complications of pregnancy
(preeclampsia, FGR, SGA) as outcome variables and
nulliparity (yes, no), first trimester smoking (yes, no), pre-
vious history of low birthweight (<2500 g) infant, chronic
hypertension (yes, no) and the diagnostic category of the
autoimmune rheumatic disease (major rheumatic disease,
undifferentiated connective tissue disease, no criteria for
diagnosis) as explanatory variables. Logistic regression wasalso used to compute the percent excess incidence
(percent population attributable risk) and the percent frac-
tion of outcome (percent population attributable fraction)
associated with autoimmune rheumatic diseases [21].Results
Out of the 5451 eligible subjects enrolled during the
period of the study, 5232 (96 %) gave their consent and
completed the questionnaire. The rate of positivity to
one or more questions was 9.8 % (511/5232). Of the 511
subjects with a positive questionnaire, 349 (68.3 %)
tested positive for autoantibodies and were sent to the
rheumatology unit for evaluation. The prevalence of the
different rheumatic diseases was 0.4 % for RA (19/5232),
0.25 % (13/5232) for SLE, 0.31 % for Sjögren’s syndrome
(16/5232), 0.3 % for primary APS (14/5232) and 0.11 %
for other miscellaneous causes (two subjects with systemic
sclerosis, one with mixed connective tissue disease one
with Wegener syndrome and one with monoarticular
arthritis). The overall prevalence of major connective
tissue disease was 1.3 % (68/5232). UCTD was the most
common unrecognized rheumatologic disorder and was
diagnosed in 2.5 % (131/5232) of subjects. Finally, 150 out
of the 349 subjects with symptoms and autoantibodies
(43 %) had insufficient criteria for a diagnosis of a definite
rheumatic disease.
Table 2 reports the distribution of symptoms and auto-
immune antibodies in the groups studied. More than
50 % of women with UCTD or a with major rheumatic
disease reported three or more symptoms; on the other
hand, 5.4 % of controls tested positive for antinuclear
antibodies at a titer of 1:80 or more. Photosensitivity and
Raynaud’s phenomenon were the most common symp-
toms among subjects diagnosed with UCTD (73/131 and
92/131) and those without a definite diagnosis (85/150
and 78/150, respectively). Of the 150 subjects without a
definite diagnosis, 116 ANA (77.3 %) positive subjects
had a clinical picture resembling UCTD but with symp-
toms lasting less than 3 years, whereas the remaining 34
(22.7 %) had an incomplete picture of a major rheumatic
disease.
After the first trimester of pregnancy, corticosteroids
and/or hydroxychloroquine were given to 23 (17.6 %)
women with UCTD and to 20 (29.4 %) with a definite
connective tissue disease. After a definite rheumatological
diagnosis, low-molecular dose heparin and/or aspirin were
administered in 18 (26.5 %) and 42 (61.8 %) of subjects
with major rheumatic diseases and 15 (11.5 %) and 48
(36.6 %) of those with UCTD, respectively. Overall, among
the 199 women with a definite rheumatic disease, heparin
was given to 26 (13.1 %) subjects with primary or second-
ary APS and to 7 (3.5 %) women with a previous throm-
botic events.
Table 2 Number of positive questionnaire answers and
autoantibodies among controls and subjects with undifferentiated
connective tissue disease, major rheumatic diseases and no
criteria for diagnosis
Controls
n = 597
UCTD
n = 131
Major rheumatic
diseases
n = 68
No criteria for
diagnosis
n = 150
N. of items N (%) N (%) N (%) N (%)
1 - 8 (61.1) 8 (11.8) -
2 - 54 (41.2) 24 (35.3) 87 (58)
>2 - 69 (52.7) 36 (52.9) 63 (42)
ANA titre
1:80 24 (4) 42 (32.1) 13 (19.1) 82 (54.6)
1:160 8 (1.3) 46 (35.1) 16 (23.5) 26 (17.3)
> 1:160 43 (32.8) 26 (38.2) 11 (7.3)
dsDNA 0 5 (3.8) 8 (11.7) 2 (1.3)
ENA 0 17 (12.9) 22 (32.4) 0
aCLIgG 0 6 (4.6) 10 (14.7) 9 (6)
aCL IgM 1 (0.16) 14 (10.7) 11 (16.2) 22 (14.6)
beta2GP1IgG 0 4 (3.05) 8 (11.7) 8 (5.3)
LAC 0 1 (0.76) 9 (13.2) 0
UCTD undifferentiated connective tissue disease, ANA antinuclear antibodies,
dsDNA anti-double stranded DNA, ENA extractable nuclear antigen antibodies,
aCL anticardiolipin autoantibodies, beta2GP1 beta2glicoprotein1, LAC
lupus anticoagulant
Table 3 Main demographic variables autoantibodies among contro
(UCTD), major rheumatic diseases and no criteria for diagnosis
Controls
n = 597
UCTD
n = 131
mean (SD) mean (SD
Maternal age (years) 33.2 (4.5) 33.6 (4.9)
Body mass index (Kg\m2) 23 (3.4) 22.8 (3.7)
Gestational age at entry (weeks) 13.1 (1.3) 13 (1.4)
Gestational age at birth (weeks) 39 (1.9) 38.4 (2.1)
Birth Weight (gr) 3242 (506) 3050 (607
N (%) N (%)
Caucasian 573 (96) 127 (97)
Black/African 21 (3.5) 3 (2.3)
Asian 3 (0.5) 1 (0.7)
Education (years)
≤8 98 (16.4) 19 (14.5)
8–13 318 (53.3) 75 (57.3)
>13 181 (30.3) 37 (28.2)
Nulliparous 417 (69.8) 80 (61.1)
First trimester smoking 83 (13.9) 26 (19.8)
Previous low birth weight infant (<2500 gm) 4 (0.67) 4 (3.1)
Chronic hypertension 7 (1.2) 6 (4.6)
SD standard deviation
p values obtained by one-way anova or chi-square test
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irrespective of diagnosis, had a lower gestational age and
birthweight than controls (Table 3). In the post-hoc
analysis, and after Bonferroni correction, gestational age
and birthweight among subjects with a major rheumatic
disease were lower when compared to the UCTD group
(p = 0.05 for both comparisons) and to subjects without
a definite diagnosis (p <0.001 and p = 0.012 for gesta-
tional age and birthweight, respectively). Nulliparity was
more common among controls than in any category of
rheumatologic disorder (p <0.05 for all comparisons),
whereas a previous low-birthweight infant was more
common among subjects with a major rheumatic disease
than in controls.
Increased placental vascular resistance, as suggested by
increased pulsatility indices in the first and second
trimester uterine artery and third trimester umbilical
artery, were higher in all the categories of rheumatic
disorders, including subjects without a definite diagno-
sis, than in controls (p <0.01 for all comparisons in the
post-hoc analysis) (Table 4). Umbilical artery PI was also
higher among major rheumatic diseases when compared
to either UCTD (p = 0.009) or to subjects without a
definite diagnosis (p = 0.017). These results were also
confirmed in the categorical analysis since the rates of
first and second trimester uterine artery bilateral notchesls and subjects with undifferentiated connective tissue disease
Major rheumatic diseases
n = 68
No criteria for diagnosis
n = 150
p
) mean (SD) mean (SD)
33.6 (4.9) 33.5 (4.5) 0.65
22.6 (3.1) 22.7 (3.1) 0.66
12.9 (1.2) 13.2 (1.4) 0.7
37.7 (2.9) 38.9 (1.99) <.001
) 2844 (664.77) 3086 (492) <.001
N (%) N (%)
64 (94) 141 (94) 0.8
4 (6) 8 (5.3)
1 (0.7)
10 (14.7) 22 (14.7) 0.9
37 (54.4) 76 (50.7)
21 (30.9) 52 (34.7)
39 (57.3) 96 (64) <.001
14 (20.6) 30 (20) 0.1
3 (4.4) 4 (2.6) 0.03
2 (2.9) 1 (0.6) 0.06
Table 4 Maternal and fetal Doppler velocimetry, and main obstetric outcomes among controls and subjects with undifferentiated
connective tissue disease (UCTD), major rheumatic diseases and no criteria for diagnosis
Controls
n = 597
UCTD
n = 131
Major rheumatic diseases
n = 68
No criteria for diagnosis
n = 150
p
mean (SD) mean (SD) mean (SD) mean (SD)
I st trimester Uterine artery PI 1.16 (0.3) 1.64 (0.3) 1.80 (0.4) 1.37 (0.4) <.001
II nd trimester Uterine artery PI 0.87 (0.4) 1.29 (0.2) 1.33 (0.3) 1.00 (0.3) <.001
III rd trimester Umbilical Artery PI 0.89 (0.1) 0.95 (0.2) 1.03 (0.3) 0.95 (0.20) <.001
N (%) N (%) N (%) N (%)
Uterine artery bilateral notch
Ist trimester 23 (3.8) 33 (25.2) 30 (44.1) 14 (9.3) <.001
IInd trimester 14 (2.3) 15 (11.5) 18 (26.5) 9 (6) <.001
Umbilical artery PI >95° percentile 25 (4.2) 21 (16) 18 (26.5) 24 (16) <.001
Miscarriage 2 (0.3) 1 (0.6) 0.6
Stillbirth 1 (0.2) 1 (1.5) 0.3
Gestational diabetes 13 (2.2) 4 (3.1) 4 (5.8) 6 (4.0) 0.35
Small for gestational age 46 (7.7) 23 (17.5) 18 (26.5) 17 (11.3) <.001
Fetal growth restriction (FGR) 25 (4.2) 21 (16) 18 (26.5) 20 (13.3) <.001
Preeclampsia 19 (3.2) 18 (13.7) 15 (22.1) 9 (6) <.001
Preclampsia or FGR 36 (6) 30 (22.9) 20 (29.4) 22 (14.6) <.001
Delivery less than 34 weeks 17 (2.8) 6 (4.6) 5 (7.4) 4 (2.6) 0.2
Cesarean section 183 (30.6) 58 (44.3) 34 (50) 46 (30.6) 0.001
SD standard deviation, PI pulsatility index
p values obtained by one-way anova or chi-square test
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were higher among all categories of rheumatic disorders
than in controls (p < 0.01 for all comparisons). In the
partition of the chi-square analysis, compared to the
negative controls, the rates of preeclampsia or FGR were
more common among all categories of rheumatic disor-
ders, including subjects without a definite diagnosis
(p <0.01 for all comparisons). Finally, the rates of SGA
infants were higher among patients with major rheumatic
diseases (p <0.001) and UCTD (p = 0.007) than in controls.
Table 5 reports the results of the logistic regression
analysis. Putative risk factors for preeclampsia and/or
fetal growth failure that differed among cases and con-
trols at p ≤ 0.1 level (nulliparity, first trimester smoking,
previous low birthweight infant and chronic hyperten-
sion) were inserted in the model as confounders. The
likelihood of either FGR or preeclampsia was five times
higher among subjects with defined rheumatic disorders,
either UCTD or a major systemic disease, than in con-
trols. The odds ratio of these two outcomes was also
higher in subjects with a definite diagnosis of a rheu-
matic disease than in those with insufficient criteria for
a diagnosis (p = 0.028). Overall, unrecognized rheumatic
diseases, major or UCTD, were associated with an excess
incidence of 3.9 cases per 100 subjects (95 % CI =
2.6–9.6), or 34 % (95 % CI = 22–44) of all cases of
either preeclampsia or FGR.The overall adjusted prevalence of SGA in the popula-
tion studied was 11.1 % (95 % CI = 9.2–13.2) (104/941).
Major rheumatic diseases and UCTD were associated
with an excess risk of SGA of 1.4 % (95 % CI = 0.6–2.1)
and 1.3 % (95 % CI = 0.4–2.3), and with attributable
fractions of 12.3 % (95 % CI = 5.2–18.8) and 12.5 %
(95 % CI = 3.5–20.4), respectively. Overall, previously
unrecognized rheumatic diseases, either major or UCTD,
were associated with a significantly increased risk of SGA
(OR = 3.1, 95 % CI = 1.96–4.95) and with an excess risk of
2.7 cases (95 % CI = 1.5–4) or 25 % (95 % CI = 12.8–34.8)
of all SGA cases.
Discussion
The results of this study have shown that unrecognized
or undiagnosed autoimmune rheumatic disorders are
rather common during the first trimester of pregnancy
and are associated with a significant number of pre-
eclampsia and fetal growth restriction cases. In parti-
cular, the 1.3 % rate of definite rheumatic diseases
detected during the first trimester of pregnancy was
responsible for 15 % of all cases of preeclampsia or
IUGR and for 12 % of all cases of SGA. After the inclu-
sion of the 2.5 % rate of UCTD detected during the first
trimester, unrecognized rheumatic disorders were respon-
sible for up to 25 % of SGA and up to 34 % of preeclamp-
sia/IUGR cases in our population. The strengths of this
Table 5 Crude incidence, odds ratio, population attributable risk and population attributable fraction of preeclampsia and/or fetal
growth restriction (FGR) in the population studied after excluding subjects with spontaneous abortions
Preeclampsia Crude incidence
(%) 95 % CI
Odds ratio
(95 % CI)
PAR (%)
95 % CI
PAF (95 % CI)
Controls/overall incidence* (n = 594) 3.2 (1.9–5) Reference 6.5 (5.1–8.1)*
Major rheumatic diseases (n = 67) 26.9 (16.8–39.1) 9.2 (4.3–19.5) 1.4 (0.6–2.1) 0.22 (0.09–0.33)
UCTD (n = 131) 13.7 (8.4–20.8) 4.6 (2.3–9.2) 1.4 (0.6–2.1) 0.21 (0.1–0.31)
Overall rheumatic diseases (n = 198) 16.7 (11.8–22.6) 6 (3.3–10.9) 2.8 (1.7–3.9) 0.43 (0.26–0.56)
No criteria for diagnosis (n = 150) 6 (2.8–11.1) 2 (0.9–4.6) 0.05 (−0.01–1.1) 0.07 (−0.03–0.17)
Fetal growth restriction (FGR)
Controls/overall incidence* 4.2 (2.8–6.1) Reference 8.8 (7.2–10.8)*
Major rheumatic diseases 26.9 (16.8–39.1) 8.8 (4.4–17.3) 1.6 (0.9–2.4) 0.18 (0.1–0.26)
UCTD 16 (10.2–23.5) 4.1 (2.2–7.8) 1.5 (0.06–2.4) 0.17 (0.07–0.26)
Overall rheumatic diseases 19.7 (14.4–25.9) 5.5 (3.2–9.5) 3.1 (1.9–4.3) 0.36 (0.22–0.47)
No criteria for diagnosis 13.4 (8.4–20) 3.6 (1.9–6.7) 1.4 (0.05–2.3) 0.16 (0.06–0.26)
Preeclampsia or FGR
Controls/overall incidence* 6.1 (4.3–8.3) Reference 11.5 (9.6–13.5)*
Major rheumatic diseases 29.9 (19.3–42.3) 6.8 (3.6–12.9) 1.7 (0.09–2.5) 0.15 (0.08–0.21)
UCTD 22.9 (16–31.1) 4.4 (2.5–7.5) 2.2 (1.1–3.2) 0.19 (0.1–0.27)
Overall rheumatic diseases 25.3 (19.4–31.9) 5.1 (3.2–8.3) 3.9 (2.6–9.6) 0.34 (0.22–0.44)
No criteria for diagnosis 14.8 (9.5–21.5) 2.7 (1.5–4.8) 1.4 (0.4–2.3) 0.1 (0.04–0.2)
UCTD undifferentiated connective tissue disease
Odds ratios (OR), population attributable risk (PAR) and population attributable fraction obtained by logistic regression analysis containing preeclampsia and/or
FGR as outcomes and category of rheumatic disorders (controls, major rheumatic diseases, UCTD, no criteria for diagnosis), nulliparity (yes, no), first trimester
smoking (yes, no), chronic hypertension (yes, no) and previous low birthweight (<2500 g) infant (yes, no) as explanatory variables. The analysis was carried out
in 941 viable pregnancies
*Overall incidence
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and the number of subjects recruited. Previous retro-
spective studies have suggested that a clinical history of
reproductive failure, preeclampsia, prematurity or FGR
increases the subsequent risk of a diagnosis of rheumatic
disease [22]. This association has prompted several
authors to postulate a causal association between adverse
reproductive events and subsequent occurrence of rheu-
matic diseases such as RA or SLE [23]. Although the
potential interference of pregnancy-associated hormonal
and metabolic modifications on the subsequent occur-
rence of rheumatic diseases cannot be entirely excluded,
other retrospective studies suggest that a poor reproduc-
tive outcome is rather a comorbidity of the long precli-
nical phase of some rheumatic diseases rather than a true
causative factor [3, 6, 7]. Our longitudinal data show that
adverse obstetric events are common, not only among
women with unrecognized rheumatic diseases with a
definite diagnosis, but also among undifferentiated or even
“early” rheumatic disorders which, without screening mea-
sures, would have been undetected.
Potential selection biases are the main limitations of the
study. We used a two-step screening approach including a
self-administered questionnaire and subsequent autoanti-
body detection, which in a pilot study demonstrated excel-
lent detection rates of rheumatic disease [8]. In addition,the validity of a similar approach has been extensively
confirmed in the diagnosis of RA, SLE and Sjögren’s syn-
drome both in Europe and in other countries [11–16].
The rate of false negatives using this method is very low
[8]; thus, the prevalence rates detected in our study should
not be biased by underdiagnosis. In addition, to avoid
overdiagnosis, we used standard definitions for the diag-
nosis of RA, SLE, Sjögren’s syndrome, systemic sclerosis,
APS and UCTD and rheumatological clinical assessments
were repeated monthly during pregnancy. The overall rate
of definite rheumatic diseases and UCTD in our study is
consistent with the 5 % rate of major rheumatic diseases
reported in the general population [1, 3], however, since
recruitment took place in a public hospital, we cannot
exclude a potential selection bias based on low socio-
economic status. Definite rheumatic diseases such as RA,
SLE or Sjögren’s syndrome can be unrecognized or un-
diagnosed for long periods of time because the symptoms
and signs are not specific and a precise diagnosis can be
difficult to achieve [2–4]. Moreover, the natural history
of these disorders follows a pattern of progression lasting
from months to years, from a preclinical non-diagnostic
phase to overt clinical disease [2, 3, 24]. Establishing
the exact moment of transition from the preclinical to
clinical phases is difficult; thus, in the general population,
rheumatic diseases can be detected at various stages of
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well-defined rheumatic disease in our population was not
surprising. UCTD, defined as the presence of at least one
clinical manifestation of a major rheumatic disease lasting
at least 3 years and a positive ANA result, was the most
frequent rheumatic disorder detected in our subjects.
Although the risk of preeclampsia and fetal growth restric-
tion associated with UCTD was lower than that associated
with major rheumatic diseases, the burden of pregnancy
complications associated with these two disorders was
similar. The group of subjects with UCTD probably
includes either women in the preclinical stage of a major
rheumatic disease or women with a stable mild rheumatic
disorder [25]. Whatever the composition of this group of
rheumatic disorders, our results confirm preliminary data
showing that UCTD is associated with an increased risk of
adverse pregnancy outcomes [26]. According to Mosca
et al., [27], the group of subjects with no criteria for a
definite diagnosis of a rheumatic disease probably contains
subjects in the early phase of stable UCTD as well as
subjects at an early phase or in a true preclinical stage of a
major rheumatic disease. Although, in our study, the
impact of this condition on the incidence of FGR or
preeclampsia was considerably lower than that of either
UCTD or major rheumatic diseases, the risk of adverse
pregnancy outcomes was higher in these subjects than in
negative controls.
Inadequate trophoblast invasion of the spiral arteries
with a subsequent defective establishment of maternal-
fetal vascularization and oxygen and nutrient exchange
is considered the probable mechanism underlying the
adverse effect of rheumatic disorders on pregnancy
outcomes [27]. A direct effect of maternal autoantibodies
on trophoblast invasiveness as well as maternal proinflam-
matory status and endothelial dysfunction seem to medi-
ate defective placentation among subjects with rheumatic
disorders [27]. The results of our study confirm these
suggestions. In fact, we found increased second trimester
pulsatility indices and bilateral notching of uterine arteries
in all categories of rheumatic disorders compared to
controls. These Doppler findings are associated with inad-
equate trophoblast invasion of myometrial spiral arteries,
leading to an increased risk of preeclampsia and FGR
[23, 27]. A vascular mechanism could also be postulated
for the adverse effect of preclinical rheumatic diseases on
pregnancy outcome. In fact, it has been demonstrated that
autoantibodies related to pre-disease stages could increase
the risk of peripheral vascular damage, leading to accele-
rated atherosclerosis and cardiovascular disease [5].
The rate of unrecognized rheumatic disorders in the
general population could be affected by the incidence of
autoimmune diseases in the population and by the time
and the frequency of contact with the health care system.
For these reasons, our results cannot be generalized toother populations. However, given their long and often
unpredictable natural history, it is likely that in the general
population of countries with a high incidence of rheu-
matic disorders, a significant proportion of subjects in the
preclinical stage of these diseases can go undetected for a
long period of time. The identification of this group of
subjects early during pregnancy could lead to a timely
treatment of rheumatic disorders and also to a prevention
of pregnancy complications [28].
Conclusions
Our data indicate that a first trimester detailed history
on symptoms suggesting a systemic connective tissue
disease can be useful in the early detection of a previ-
ously undiagnosed systemic rheumatic disease. Screen-
ing measures for rheumatic disorders have the potential
to improve both disease outcomes and comorbidities
such as cardiovascular disease and adverse reproductive
consequences [3, 29]. However, factors regulating the
performance of a screening approach such as tests to be
used, the population to be tested, the magnitude of net
benefits and the harms associated with screening for
rheumatic disorders are still uncertain [2–4]. Future
studies may clarify if screening programs are applicable
to populations at risk and whether the identification of
subjects with rheumatic disorders at various stages of
the disease could translate to a better prognosis and the
prevention of associated comorbidities such as preg-
nancy complications.
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